## BMRN: BioMarin Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.8% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($50.42)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Icon Advisers Inc. Co. Has $973,000 Position in BioMarin Pharmaceutical Inc. $BMRN**
- Source: MarketBeat | 20251205T011019 | Somewhat-Bearish | Relevance: 100%
- Icon Advisers Inc. Co. significantly reduced its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 28.3% in the second quarter, now holding 17,706 shares valued at $973,000. Despite the company missing its quarterly EPS and revenue estimates, it issued strong FY2025 guidance. Analysts maintain a "Moderate Buy" rating with a target price considerably higher than its current share price, suggesting potential upside.

**2. BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory**
- Source: Finviz | 20251204T141500 | Bullish | Relevance: 99%
- BioMarin Pharmaceutical Inc. (BMRN) appears materially undervalued despite strong operational performance, with institutional ownership of 99.6% and consistent outperformance of analyst expectations. The company, trading near 52-week lows, reported significant EPS growth in Q2 2025 due to a successful restructuring, and management anticipates further benefits and has upgraded guidance. Its orphan drug portfolio faces limited competition and has upcoming clinical trial conclusions expected to lead to approvals, presenting a compelling investment opportunity despite a commonly cited competitive headwind.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-03 | Leerink Partner | $60 | $82 | -27% |
| 2025-11-06 | Stifel | $61 | $73 | -16% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-03 | Leerink Partner | down | Market Perform |
| 2025-11-06 | Stifel | down | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($1.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Blackrock Inc.: 11.5% (-8.1%)
- Vanguard Group Inc: 9.7% (-2.2%)
- Primecap Management : 7.9% (-3.4%)
- Dodge & Cox Inc.: 7.6% (-2.8%)
- State Street Corpora: 4.6% (-0.9%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.7% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 9.1% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.46 indicates undervaluation relative to growth. Forward P/E 10.1x attractive for 49% earnings growth. Quality metrics strong (margin 17%). Balance sheet: strong liquidity (4.8x), low leverage (D/E 0.26). Analyst sentiment negative (2 target cuts vs 0 raises). Insider selling cluster ($1.1M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.5B |
| Beta | 0.30 |
| 52W Range | $50.76 - $73.51 |
| Short Interest | 5.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.46 |
| Forward P/E | 10.1 |
| Current P/E | 14.9 |
| YoY Growth | 48.6% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from 0.8% to -3.8% (-4.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.8pp (needs >4.0% for momentum thesis). Below SMA200 (0.91x), long-term trend not supportive. RSI neutral at 46. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.84% (CS: 19) | Weak |
| RSI_14 | 46.2 | Neutral |
| MACD Histogram | -0.11 | Bearish |
| vs SMA20 | 0.984x | Below |
| vs SMA50 | 0.992x | Below |
| vs SMA200 | 0.909x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $53.40
- **Stop Loss:** $50.42 (5.6% risk)
- **Target:** $56.38 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 167
- **Position Value:** $8,917.80
- **Portfolio %:** 8.92%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-19 (Est: $0.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.34 | $0.12 | -64.3% |
| 2025Q2 | $1.03 | $1.44 | +39.4% |
| 2025Q1 | $0.95 | $1.13 | +18.6% |
| 2024Q4 | $0.74 | $0.92 | +24.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*